Biodistribution and PET imaging of labeled bispecific T cell engaging antibody targeting EpCAM

Journal of Nuclear Medicine

Volumn 57, Issue 5, 2016, Pages 812-817

  Warnders, Frank J ^a   Waaijer, Stijn J H ^a   Pool, Martin ^a   De Hooge, Marjolijn N Lub ^a   Friedrich, Matthias ^b   Van Scheltinga, Anton G T Terwisscha ^a   Deegen, Petra ^b   Stienen, Sabine K ^b   Pieslor, Peter C ^c   Cheung, H Kam ^c   Kosterink, Jos G W ^a,d   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Amgen Research GmbH   (Germany)

^c AMGEN INC   (United States)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

89Zr; BiTE; Fluorescence; Imaging; PET

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; FLUORESCENT DYE; ZIRCONIUM 89; MONOCLONAL ANTIBODY; RADIOISOTOPE; ZIRCONIUM;

ANIMAL EXPERIMENT; ANTIBODY LABELING; ARTICLE; CANCER CELL; CELL DEATH; COLORECTAL CANCER; CONTROLLED STUDY; CROSS LINKING; EX VIVO STUDY; FLUORESCENCE IMAGING SYSTEM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IN VIVO STUDY; KINETICS; MALE; MOUSE; NEAR INFRARED IMAGING SYSTEM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; T LYMPHOCYTE; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; HL-60 CELL LINE; HT-29 CELL LINE; HUMAN; IMMUNOLOGY; ISOTOPE LABELING; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; EPITHELIAL CELL ADHESION MOLECULE; HL-60 CELLS; HT29 CELLS; HUMANS; ISOTOPE LABELING; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; T-LYMPHOCYTES; TISSUE DISTRIBUTION; ZIRCONIUM;

EID: 84966728674     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.168153     Document Type: Article

References (22)

1. Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the development of cancer immunotherapies. Trends Immunol. 2013;34:90-98.
2. Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumorinduced immune suppression. Cancer Metastasis Rev. 2011;30:125-140.
3. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003;195:346-355.
4. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013;17:385-392.
5. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006;43:763-771.
6. Dreier T, Baeuerle PA, Fichtner I, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol. 2003;170:4397-4402.
7. Haas C, Krinner E, Brischwein K, et al. Mode of cytotoxic action of T cellengaging BiTE antibody MT110. Immunobiology. 2009;214:441-453.
8. Petsch S, Gires O, Ruttinger D, et al. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. MAbs. 2011;3:31-37.
9. Went PT, Lugli A, Meier S, et al. Frequent EpCAM protein expression in human carcinomas. Hum Pathol. 2004;35:122-128.
10. Brischwein K, Schlereth B, Guller B, et al. MT110: A novel bispecific singlechain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006;43:1129-1143.
11. Fiedler WM, Kebenko M, Goebeler M-E, et al. A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. J Clin Oncol. 2012;30 (suppl):2504.
12. Lamberts LE, Williams SP, Terwisscha Van Scheltinga AG, et al. Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol. 2015;33:1491-1504.
13. Terwisscha Van Scheltinga AG, Van Dam GM, Nagengast WB, et al. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med. 2011;52:1778-1785.
14. Thurber GM, Weissleder R. Quantitating antibody uptake in vivo: Conditional dependence on antigen expression levels. Mol Imaging Biol. 2011;13:623-632.
15. Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther. 2011;11:843-853.
16. Eder M, Knackmuss S, Le Gall F, et al. 68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur J Nucl Med Mol Imaging. 2010;37:1397-1407.
17. Terwisscha Van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, et al. In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer. J Nucl Med. 2014;55: 665-671.
18. Terwisscha Van Scheltinga AG, Lub-de Hooge MN, Abiraj K, et al. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody 89Zr-RG7116. MAbs. 2014;6:1051-1058.
19. Dijkers EC, Kosterink JG, Rademaker AP, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974-981.
20. DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: Applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res. 2011;13: R44.
21. List T, Neri D. Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site. MAbs. 2012;4:775-783.
22. Tibben JG, Boerman OC, Massuger LF, Schijf CP, Claessens RA, Corstens FH. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients. Int J Cancer. 1996;66:477-483.